RETRACTED: LSAMP-AS1 binds to microRNA-183–5p to suppress the progression of prostate cancer by up-regulating the tumor suppressor DCN

Abstract

Background: : Prostate cancer (PCa) is a leading cause of cancer-related death in males. Aberrant expression of long noncoding RNAs (lncRNAs) is frequently reported in human malignancies. This study was performed to explore the role of LSAMP-AS1 in epithelial-mesenchymal transition (EMT), proliferation, migration and invasion of PCa cells. Methods: : Initially, the differentially expressed lncRNAs in PCa were screened out by microarray analysis. The clinicopathological and prognostic significance of LSAMP-AS1 was evaluated. LSAMP-AS1 was overexpressed or silenced to investigate the roles in EMT, proliferation, migration and invasion of PCa cells. Moreover, the relationships between LSAMP-AS1 and miR-183-5p, as well as miR-183-5p and decorin (DCN) were characterized. The tumorigenicity of PCa cells was verified in nude mice. Results: : LSAMP-AS1 was poorly expressed in PCa tissues and cells. Low expression of LSAMP-AS1 was indicative of poor overall survival and disease-free survival, and related to Gleason score, TNM stage, and risk stratification. Over-expressed LSAMP-AS1 inhibited EMT, proliferation, migration and invasion of PCa cells, as well as tumor growth in nude mice. Meanwhile, over-expression of LSAMP-AS1 resulted in upregulation of E-cadherin and down-regulation of Vimentin, N-cadherin, Ki67, PCNA, MMP-2, MMP-9, Ezrin and Fascin. Notably, LSAMP-AS1 competitively bound to miR-183-5p which directly targets DCN. It was confirmed that the inhibitory effect of LSAMP-AS1 on PCa cells was achieved by binding to miR-183-5p, thus promoting the expression of DCN. Conclusion: : LSAMP-AS1 up-regulates the DCN gene by competitively binding to miR-183-5p, thus inhibiting EMT, proliferation, migration and invasion of PCa cells.

LINC01006 facilitates cell proliferation, migration and invasion in prostate cancer through targeting miR-34a-5p to up-regulate DAAM1

“…For the last few years, quantities of lncRNAs have been reported to be crucial regulators in cellular processes of various cancers [ 5 – 7 ]. For instance, a novel lncRNA LSAMP-AS1 is involved in PCa process via targeting miR-183-5p/DCN axis [ 8 ]. LncRNA RHPN1-AS1 has been claimed to accelerate the breast cancer development [ 9 ].…”

LINC01006 facilitates cell proliferation, migration and invasion in prostate cancer through targeting miR-34a-5p to up-regulate DAAM1

“…For the last few years, quantities of lncRNAs have been reported to be crucial regulators in cellular processes of various cancers [5][6][7]. For instance, a novel lncRNA LSAMP-AS1 is involved in PCa process via targeting miR-183-5p/DCN axis [8]. LncRNA RHPN1-AS1 has been claimed to accelerate the breast cancer development [9].…”

MicroRNA-183-5p contributes to malignant progression through targeting PDCD4 in human hepatocellular carcinoma

“…Furthermore, past researches have shown that aberrant expression of miRNAs would contribute to malignant development of human HCC [ 23–25 ]. MicroRNA-183-5p (miR-183-5p), a novel cancer-related miRNA, has been identified to act as a critical player in multiple types of human malignancies, including pancreatic adenocarcinoma [ 26 ], prostate cancer [ 27 ], colorectal cancer [ 28 , 29 ], renal cell cancer [ 30 ] and non-small cell lung cancer [ 31 ]; nevertheless, its biological role in HCC remains largely unclear.…”